|
Debt (Details Narrative) (USD $)
|
Jun. 30, 2012
|
Dec. 31, 2011
|
Jun. 30, 2011
|
|---|---|---|---|
| Fair value of warrants | $ 72,000 | $ 39,000 | |
| Debentures outstanding | 55,000 | ||
| Warrant for number of shares to be purchased | 5,000,000 | ||
| Exercise price of warrant | $ 0.03 | ||
| Membership interest issued to Dr. Repine | 40.00% | ||
| Licensing the assigned IP to a pharmaceutical company | 1,000,000 | ||
| Completion of Phase I Clinical Trial | 250,000 | ||
| Completion of Phase II Clinical Trial | 1,000,000 | ||
| Completion of pivotal Phase III Clinical Trial | 1,500,000 | ||
| Receipt of FDA Marketing approval | 3,000,000 | ||
| Entering into a distribution agreement with nutraceutical or similar company | $ 100,000 | ||
| Gross sales of products utilizing EGT | 5.00% | ||
|
ClassAWarrantsMember
|
|||
| Warrants outstanding | 14,900,000 | ||
|
ClassBWarrantsMember
|
|||
| Warrants outstanding | 16,750,000 |
| X | ||||||||||
|
- Definition
Custom Element. No definition available.
|
| X | ||||||||||
|
- Definition
Custom Element. No definition available.
|
| X | ||||||||||
|
- Definition
Custom Element. No definition available.
|
| X | ||||||||||
|
- Definition
Custom Element. No definition available.
|
| X | ||||||||||
|
- Definition
Custom Element. No definition available.
|
| X | ||||||||||
|
- Definition
Custom Element. No definition available.
|
| X | ||||||||||
|
- Definition
Custom Element. No definition available.
|
| X | ||||||||||
|
- Definition
Custom Element. No definition available.
|
| X | ||||||||||
|
- Definition
Custom Element. No definition available.
|
| X | ||||||||||
|
- Definition
Custom Element. No definition available.
|
| X | ||||||||||
|
- Definition
Aggregate amount of each class of warrants or rights outstanding. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity. No definition available.
|
| X | ||||||||||
|
- Definition
Portion of the balance sheet assertion valued at fair value by the entity whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission. This item represents warrants not settleable in cash classified as equity. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|